Masafumi Fukagawa

List of Publications by Citations

252 papers	7,506 citations	45 h-index	77 g-index
271 ext. papers	8,712 ext. citations	4.4 avg, IF	5.93 L-index

#	Paper	IF	Citations
252	Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. *Kidney International*, **2017**, 92, 26-36	9.9	461
251	Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. *American Journal of Kidney Diseases*, **2004**, 44, 250-6	7.4	272
250	Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. *Therapeutic Apheresis and Dialysis*, **2013**, 17, 247-88	1.9	220
249	p-Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase. *Kidney International*, **2013**, 83, 582-92	9.9	219
248	Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. *Kidney International*, **2010**, 77, 232-8	9.9	212
247	Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. *Clinical Journal of the American Society of Nephrology: CJASN*, **2015**, 10, 98-109	6.9	174
246	Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. *Kidney International*, **2005**, 67, 1171-8	9.9	153
245	Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. *American Journal of Kidney Diseases*, **2002**, 39, 525-32	7.4	136
244	Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients. *Nephron*, **1994**, 68, 221-8	3.3	124
243	Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. *American Journal of Kidney Diseases*, **2004**, 43, 558-65	7.4	122
242	FGF23-parathyroid interaction: implications in chronic kidney disease. *Kidney International*, **2010**, 77, 292-8	9.9	116
241	Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. *Therapeutic Apheresis and Dialysis*, **2005**, 9, 336-9	1.9	116
240	Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. *American Journal of Kidney Diseases*, **2011**, 57, 422-31	7.4	111
239	Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. *Nephrology Dialysis Transplantation*, **2012**, 27, 784-90	4.3	109
238	Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. *Nephrology Dialysis Transplantation*, **2008**, 23, 328-35	4.3	108
237	Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism. *Kidney International*, **2015**, 88, 350-9	9.9	107
236	Oral charcoal adsorbent (AST-120) prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress. *Nephrology Dialysis Transplantation*, **2009**, 24, 2089-95	4.3	107

235	Role of oxidative stress in diabetic bone disorder. *Bone*, **2009**, 45 Suppl 1, S35-8	4.7	107
234	Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients. *Therapeutic Apheresis and Dialysis*, **2013**, 17, 221-8	1.9	101
233	Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. *Kidney International*, **2005**, 67, 1120-5	9.9	97
232	Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism. *Clinical Journal of the American Society of Nephrology: CJASN*, **2010**, 5, 2305-14	6.9	94
231	Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. *Nephron Clinical Practice*, **2005**, 101, c94-9		88
230	Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. *Clinical Journal of the American Society of Nephrology: CJASN*, **2014**, 9, 543-52	6.9	86
229	The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE-/-) mice. *Atherosclerosis*, **2009**, 205, 55-62	3.1	83
228	Indoxyl sulfate potentiates skeletal muscle atrophy by inducing the oxidative stress-mediated expression of myostatin and atrogin-1. *Scientific Reports*, **2016**, 6, 32084	4.9	74
227	The role of FGF23 in CKD--with or without Klotho. *Nature Reviews Nephrology*, **2012**, 8, 484-90	14.9	73
226	Potential therapeutic interventions for chronic kidney disease-associated sarcopenia via indoxyl sulfate-induced mitochondrial dysfunction. *Journal of Cachexia, Sarcopenia and Muscle*, **2017**, 8, 735-747	10.3	71
225	Reduction of functioning parathyroid cell mass by ethanol injection in chronic dialysis patients. *Kidney International*, **1994**, 46, 1110-7	9.9	70
224	Changes in chemical composition of cortical bone associated with bone fragility in rat model with chronic kidney disease. *Bone*, **2011**, 48, 1260-7	4.7	67
223	Downregulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover bone. *Nephrology Dialysis Transplantation*, **2005**, 20, 1904-11	4.3	66
222	Prognosis of parathyroid function after successful percutaneous ethanol injection therapy guided by color Doppler flow mapping in chronic dialysis patients. *American Journal of Kidney Diseases*, **1999**, 33, 1091-9	7.4	66
221	Role of oxidative stress and indoxyl sulfate in progression of cardiovascular disease in chronic kidney disease. *Therapeutic Apheresis and Dialysis*, **2011**, 15, 125-8	1.9	62
220	Administration of oral charcoal adsorbent (AST-120) suppresses low-turnover bone progression in uraemic rats. *Nephrology Dialysis Transplantation*, **2006**, 21, 2768-74	4.3	62
219	p-Cresyl sulfate induces osteoblast dysfunction through activating JNK and p38 MAPK pathways. *Bone*, **2013**, 56, 347-54	4.7	61
218	A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis. *Nephrology Dialysis Transplantation*, **2014**, 29, 1053-60	4.3	59

217	Phosphate-a poison for humans?. *Kidney International*, **2016**, 90, 753-63	9.9	58
216	Role of Uremic Toxins for Kidney, Cardiovascular, and Bone Dysfunction. *Toxins*, **2018**, 10,	4.9	57
215	Prevention of enhanced parathyroid hormone secretion, synthesis and hyperplasia by mild dietary phosphorus restriction in early chronic renal failure in rats: possible direct role of phosphorus. *Nephron*, **1995**, 70, 242-8	3.3	57
214	Effect of intravenous saccharated ferric oxide on serum FGF23 and mineral metabolism in hemodialysis patients. *American Journal of Nephrology*, **2011**, 33, 421-6	4.6	56
213	In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)2 vitamin D3. *Nephrology Dialysis Transplantation*, **2003**, 18, 1770-6	4.3	54
212	Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding. *American Journal of Kidney Diseases*, **2014**, 63, 979-87	7.4	53
211	Uremic osteoporosis. *Kidney International Supplements*, **2013**, 3, 446-450	6.3	51
210	22-Oxacalcitriol prevents progression of endothelial dysfunction through antioxidative effects in rats with type 2 diabetes and early-stage nephropathy. *Nephrology Dialysis Transplantation*, **2013**, 28, 1166-74	4.3	50
209	A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia. *Journal of the American Society of Nephrology: JASN*, **2019**, 30, 1723-1733	12.7	49
208	p-Cresyl sulfate, a uremic toxin, causes vascular endothelial and smooth muscle cell damages by inducing oxidative stress. *Pharmacology Research and Perspectives*, **2015**, 3, e00092	3.1	45
207	Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. *American Journal of Kidney Diseases*, **2004**, 44, 481-7	7.4	45
206	Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism. *Kidney International*, **2018**, 94, 818-825	9.9	44
205	Comparison of parathyroid hormone levels from the intact and whole parathyroid hormone assays after parathyroidectomy for primary and secondary hyperparathyroidism. *Surgery*, **2004**, 135, 149-56	3.6	43
204	Accumulated uremic toxins attenuate bone mechanical properties in rats with chronic kidney disease. *Bone*, **2013**, 57, 477-83	4.7	42
203	PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism. *Scientific Reports*, **2016**, 6, 19612	4.9	40
202	A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients. *Nephrology Dialysis Transplantation*, **2017**, 32, 1723-1730	4.3	39
201	Altered material properties are responsible for bone fragility in rats with chronic kidney injury. *Bone*, **2015**, 81, 247-254	4.7	38
200	A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro. *PLoS ONE*, **2018**, 13, e0195316	3.7	38

199	Long-term safety and efficacy of a novel iron-containing phosphate binder, JTT-751, in patients receiving hemodialysis. *Journal of Renal Nutrition*, **2014**, 24, 261-7	3	38
198	Diseases of the parathyroid gland in chronic kidney disease. *Clinical and Experimental Nephrology*, **2011**, 15, 797-809	2.5	38
197	Oxidative and nitrosative stress and progression of diabetic nephropathy in type 2 diabetes. *American Journal of Nephrology*, **2010**, 31, 342-52	4.6	38
196	Direct injections of calcitriol into enlarged parathyroid glands in chronic dialysis patients with severe parathyroid hyperfunction. *Nephrology*, **1995**, 1, 563-567	2.2	38
195	Impact of parathyroidectomy on serum FGF23 and soluble Klotho in hemodialysis patients with severe secondary hyperparathyroidism. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, E652-8	5.6	37
194	Comparison of intact PTH assay and whole PTH assay in long-term dialysis patients. *American Journal of Kidney Diseases*, **2001**, 38, S172-4	7.4	36
193	Effect of Oral Alfacalcidol on Clinical Outcomes in Patients Without Secondary Hyperparathyroidism Receiving Maintenance Hemodialysis: The J-DAVID Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2018**, 320, 2325-2334	27.4	36
192	A human serum albumin-thioredoxin fusion protein prevents experimental contrast-induced nephropathy. *Kidney International*, **2013**, 83, 446-54	9.9	35
191	Uremic Toxicity and Bone in CKD. *Journal of Nephrology*, **2017**, 30, 623-627	4.8	34
190	Albumin fusion renders thioredoxin an effective anti-oxidative and anti-inflammatory agent for preventing cisplatin-induced nephrotoxicity. *Biochimica Et Biophysica Acta - General Subjects*, **2014**, 1840, 1152-62	4	34
189	Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis. *Contributions To Nephrology*, **2013**, 180, 110-23	1.6	34
188	Cost-effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism in Japan. *American Journal of Kidney Diseases*, **2012**, 60, 262-71	7.4	34
187	Use of renin-angiotensin system inhibitors is associated with reduction of fracture risk in hemodialysis patients. *PLoS ONE*, **2015**, 10, e0122691	3.7	34
186	Renoprotective effect of long acting thioredoxin by modulating oxidative stress and macrophage migration inhibitory factor against rhabdomyolysis-associated acute kidney injury. *Scientific Reports* , **2015**, 5, 14471	4.9	32
185	Mineral metabolism management in hemodialysis patients with secondary hyperparathyroidism in Japan: baseline data from the MBD-5D. *American Journal of Nephrology*, **2011**, 33, 427-37	4.6	32
184	New insights into the role of fibroblast growth factor 23 in chronic kidney disease. *Journal of Nephrology*, **2010**, 23, 619-25	4.8	32
183	Management of secondary hyperparathyroidism: how and why?. *Clinical and Experimental Nephrology*, **2017**, 21, 37-45	2.5	31
182	Uremic toxins and oral adsorbents. *Therapeutic Apheresis and Dialysis*, **2011**, 15, 132-4	1.9	31

181	The kidney and bone metabolism: NephrologistsPpoint of view. *Journal of Bone and Mineral Metabolism*, **2006**, 24, 434-8	2.9	31
180	Down-regulation of ABCG2, a urate exporter, by parathyroid hormone enhances urate accumulation in secondary hyperparathyroidism. *Kidney International*, **2017**, 91, 658-670	9.9	30
179	Skeletal resistance to pth as a basic abnormality underlying uremic bone diseases. *American Journal of Kidney Diseases*, **2001**, 38, S152-5	7.4	30
178	Chronic kidney disease and bone metabolism. *Journal of Bone and Mineral Metabolism*, **2015**, 33, 245-52	2.9	29
177	Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: A randomized, open-label, multicentre, 12-week phase III study. *Nephrology*, **2017**, 22, 293-300	2.2	29
176	Survival advantage of lanthanum carbonate for hemodialysis patients with uncontrolled hyperphosphatemia. *Nephrology Dialysis Transplantation*, **2015**, 30, 107-14	4.3	29
175	Effects of AST-120 on left ventricular mass in predialysis patients. *American Journal of Nephrology*, **2011**, 33, 218-23	4.6	29
174	Treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). *Internal Medicine*, **2008** , 47, 989-94	1.1	29
173	Effects of cinacalcet treatment on serum soluble Klotho levels in haemodialysis patients with secondary hyperparathyroidism. *Nephrology Dialysis Transplantation*, **2012**, 27, 1967-9	4.3	28
172	Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D study. *Clinical Journal of the American Society of Nephrology: CJASN*, **2012**, 7, 1473-80	6.9	27
171	Overproduction and secretion of a novel amino-terminal form of parathyroid hormone from a severe type of parathyroid hyperplasia in uremia. *Clinical Journal of the American Society of Nephrology: CJASN*, **2006**, 1, 525-31	6.9	27
170	Management of patients with advanced secondary hyperparathyroidism: the Japanese approach. *Nephrology Dialysis Transplantation*, **2002**, 17, 1553-7	4.3	27
169	Emerging Association Between Parathyroid Hormone and Anemia in Hemodialysis Patients. *Therapeutic Apheresis and Dialysis*, **2018**, 22, 242-245	1.9	27
168	Vitamin D receptor activator reduces oxidative stress in hemodialysis patients with secondary hyperparathyroidism. *Therapeutic Apheresis and Dialysis*, **2011**, 15, 161-8	1.9	26
167	The relative role of fibroblast growth factor 23 and parathyroid hormone in predicting future hypophosphatemia and hypercalcemia after living donor kidney transplantation: a 1-year prospective observational study. *Nephrology Dialysis Transplantation*, **2011**, 26, 2691-5	4.3	26
166	Comparison between whole and intact parathyroid hormone assays. *Therapeutic Apheresis and Dialysis*, **2011**, 15 Suppl 1, 42-9	1.9	25
165	Association between indoxyl sulfate and skeletal resistance in hemodialysis patients. *Therapeutic Apheresis and Dialysis*, **2010**, 14, 417-23	1.9	25
164	Putative role of asymmetric dimethylarginine in microvascular disease of kidney and heart in hypertensive patients. *American Journal of Hypertension*, **2008**, 21, 650-6	2.3	25

163	Is aplastic osteodystrophy a disease of malnutrition?. *Current Opinion in Nephrology and Hypertension*, **2000**, 9, 363-7	3.5	25
162	Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan. *Clinical Journal of the American Society of Nephrology: CJASN*, **2011**, 6, 1375-84	6.9	23
161	Cost-effectiveness of alendronate for the treatment of osteopenic postmenopausal women in Japan. *Journal of Bone and Mineral Research*, **2013**, 28, 395-403	6.3	22
160	Decreases in PTH in Japanese hemodialysis patients with secondary hyperparathyroidism: associations with changing practice patterns. *Clinical Journal of the American Society of Nephrology: CJASN*, **2011**, 6, 2280-8	6.9	22
159	Sequential changes in plasma intact and whole parathyroid hormone levels during parathyroidectomy for secondary hyperparathyroidism. *World Journal of Surgery*, **2005**, 29, 169-73	3.3	22
158	Etelcalcetide for the treatment of secondary hyperparathyroidism. *Expert Opinion on Pharmacotherapy*, **2017**, 18, 529-534	4	21
157	Mineral and bone disorders outcomes study for Japanese chronic kidney disease stage 5D patients: rationale and study design. *Therapeutic Apheresis and Dialysis*, **2011**, 15, 169-75	1.9	21
156	2017 Kidney Disease: Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update Implementation: Asia Summit Conference Report. *Kidney International Reports*, **2019**, 4, 1523-1537	4.1	20
155	Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism. *Clinical and Experimental Nephrology*, **2018**, 22, 426-436	2.5	20
154	Initiation of Sevelamer and Mortality among Hemodialysis Patients Treated with Calcium-Based Phosphate Binders. *Clinical Journal of the American Society of Nephrology: CJASN*, **2017**, 12, 1489-1497	6.9	20
153	Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: A 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride. *Nephrology*, **2011**, 16, 743-50	2.2	20
152	Pirfenidone prevents the progression of irreversible glomerular sclerotic lesions in rats. *Nephrology* , **1997**, 3, 315-322	2.2	20
151	A collaborative, individual-level analysis compared longitudinal outcomes across the International Network of Chronic Kidney Disease (iNETCKD) cohorts. *Kidney International*, **2019**, 96, 1217-1233	9.9	19
150	Nephrology in earthquakes: sharing experiences and information. *Clinical Journal of the American Society of Nephrology: CJASN*, **2007**, 2, 803-8	6.9	19
149	Coronary plaque morphology using virtual histology-intravascular ultrasound analysis in hemodialysis patients. *Therapeutic Apheresis and Dialysis*, **2011**, 15, 44-50	1.9	18
148	Circulating 1-84 PTH and large C-terminal PTH fragment levels in uremia. *Clinical and Experimental Nephrology*, **2003**, 7, 144-9	2.5	18
147	Nutritional status and survival of maintenance hemodialysis patients receiving lanthanum carbonate. *Nephrology Dialysis Transplantation*, **2019**, 34, 318-325	4.3	16
146	Renin-Angiotensin system inhibitors reduce serum asymmetric dimethylarginine levels and oxidative stress in normotensive patients with chronic kidney disease. *Nephron Extra*, **2014**, 4, 18-25		16

145	Parathyroid hormone contributes to the down-regulation of cytochrome P450 3A through the cAMP/PI3K/PKC/PKA/NF-B signaling pathway in secondary hyperparathyroidism. *Biochemical Pharmacology*, **2017**, 145, 192-201	6	16
144	Natural history of mineral and bone disorders after living-donor kidney transplantation: a one-year prospective observational study. *Therapeutic Apheresis and Dialysis*, **2011**, 15, 481-7	1.9	16
143	Effectiveness of (2)-microglobulin adsorption column in treating dialysis-related amyloidosis: a multicenter study. *Blood Purification*, **2011**, 32, 317-22	3.1	16
142	The negative Ca(2+) balance is involved in the stimulation of PTH secretion. *Nephron*, **2002**, 92, 86-90	3.3	16
141	Effects of Secondary Hyperparathyroidism Treatment on Improvement in Anemia: Results from the MBD-5D Study. *PLoS ONE*, **2016**, 11, e0164865	3.7	16
140	JTT-751 for treatment of patients with hyperphosphatemia on peritoneal dialysis. *Nephron Clinical Practice*, **2014**, 128, 135-40		15
139	Fetuin-mineral complex: a new potential biomarker for vascular calcification?. *Kidney International*, **2009**, 75, 874-6	9.9	15
138	Correlation of enhanced cell proliferation with decreased density of vitamin D receptor in parathyroid hyperplasia in chronic dialysis patients. *Nephrology*, **1997**, 3, 279-284	2.2	15
137	Regulation of parathyroid function in chronic kidney disease (CKD). *Clinical and Experimental Nephrology*, **2006**, 10, 175-9	2.5	15
136	Impact of longer term phosphorus control on cardiovascular mortality in hemodialysis patients using an area under the curve approach: results from the DOPPS. *Nephrology Dialysis Transplantation*, **2020**, 35, 1794-1801	4.3	14
135	Cinacalcet induces apoptosis in parathyroid cells in patients with secondary hyperparathyroidism: histological and cytological analyses. *Nephron Clinical Practice*, **2013**, 124, 224-31		14
134	Role of uremic toxins and oxidative stress in the development of chronic kidney disease-mineral and bone disorder. *Journal of Renal Nutrition*, **2012**, 22, 98-101	3	14
133	Regression of parathyroid hyperplasia by calcimimetics--fact or illusion?. *Nephrology Dialysis Transplantation*, **2009**, 24, 707-9	4.3	14
132	Impact of cinacalcet hydrochloride on the achievement of the Japanese Society for Dialysis Therapy (JSDT) guideline targets: a post-hoc analysis of the KRN1493 study. *Therapeutic Apheresis and Dialysis*, **2008**, 12 Suppl 1, S44-9	1.9	14
131	Resurgence of parathyroidectomy: evidence and outcomes. *Current Opinion in Nephrology and Hypertension*, **2017**, 26, 243-249	3.5	13
130	Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism. *Therapeutic Apheresis and Dialysis*, **2015**, 19, 225-34	1.9	13
129	Spontaneous remission of severe hyperparathyroidism with normalization of the reversed whole PTH/intact PTH ratio in a haemodialysis patient. *Nephrology Dialysis Transplantation*, **2008**, 23, 1760-2	4.3	13
128	Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study. *PLoS ONE*, **2018**, 13, e0204896	3.7	13

127	Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis. *Scientific Reports*, **2019**, 9, 6410	4.9	12
126	Mineral and bone disorders in kidney transplant recipients: reversible, irreversible, and de novo abnormalities. *Clinical and Experimental Nephrology*, **2015**, 19, 543-55	2.5	12
125	Vitamin D and secreted Klotho: a long-awaited panacea for vascular calcification?. *Kidney International*, **2012**, 82, 1248-50	9.9	11
124	Impact of cinacalcet introduction on MBD management: the MBD-5D study in Japan. *Kidney International Supplements*, **2013**, 3, 436-441	6.3	11
123	The Prevalence of 25-hydroxyvitamin D Deficiency in Japanese Patients with Diabetic Nephropathy. *Internal Medicine*, **2016**, 55, 2555-62	1.1	11
122	Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study. *Clinical Drug Investigation*, **2018**, 38, 945-954	3.2	11
121	Secondary Hyperparathyroidism and Protein-Energy Wasting in End-Stage Renal Disease. *Therapeutic Apheresis and Dialysis*, **2018**, 22, 246-250	1.9	10
120	Autophagy: a two-edged sword in diabetes mellitus. *Biochemical Journal*, **2013**, 456, e1-3	3.8	10
119	Association of serum bicarbonate with bone fractures in hemodialysis patients: the mineral and bone disorder outcomes study for Japanese CKD stage 5D patients (MBD-5D). *Nephron Clinical Practice*, **2014**, 128, 79-87		10
118	Extracorporeal albumin dialysis. *Therapeutic Apheresis and Dialysis*, **2004**, 8, 217-22	1.9	10
117	Skeletal resistance to parathyroid hormone as a background abnormality in uremia. *Nephrology*, **2003**, 8 Suppl, S50-2	2.2	10
116	Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism. *Therapeutic Apheresis and Dialysis*, **2020**, 24, 248-257	1.9	10
115	Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients. *Clinical and Experimental Nephrology*, **2019**, 23, 258-267	2.5	10
114	Effects of the Intravenous Calcimimetic Etelcalcetide on Bone Turnover and Serum Fibroblast Growth Factor 23: Post Hoc Analysis of an Open-label Study. *Clinical Therapeutics*, **2018**, 40, 2099-2111	3.5	10
113	Mineral and bone disorder management in hemodialysis patients: comparing PTH control practices in Japan with Europe and North America: the Dialysis Outcomes and Practice Patterns Study (DOPPS). *BMC Nephrology*, **2018**, 19, 253	2.7	10
112	Efficacy and safety of SBR759, a novel calcium-free, iron (III)-based phosphate binder, versus placebo in chronic kidney disease stage V Japanese patients on maintenance renal replacement therapy. *Clinical and Experimental Nephrology*, **2014**, 18, 135-43	2.5	9
111	Hyperparathyroidism in chronic kidney disease patients: an update on current pharmacotherapy. *Expert Opinion on Pharmacotherapy*, **2013**, 14, 863-71	4	9
110	A Japanese approach for CKD-MBD. *Kidney International Supplements*, **2013**, 3, 451-456	6.3	9

109	1,25-dihydroxyvitamin D synthesis after renal transplantation: the role of fibroblast growth factor 23 and cyclosporine. *Clinical Transplantation*, **2009**, 23, 368-74	3.8	9
108	Critical issues of PTH assays in CKD. *Bone*, **2009**, 44, 666-70	4.7	9
107	Assessment of CYP-Mediated Drug Interactions for Evocalcet, a New Calcimimetic Agent, Based on In Vitro Investigations and a Cocktail Study in Humans. *Clinical and Translational Science*, **2019**, 12, 20-27	4.9	9
106	Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan. *Clinical Pharmacology: Advances and Applications*, **2018**, 10, 101-111	1.5	9
105	Critical Governance Issue of Parathyroid Hormone Assays and its Selection in the Management of Chronic Kidney Disease Mineral and Bone Disorders. *Therapeutic Apheresis and Dialysis*, **2018**, 22, 220-228	1.9	9
104	Long-Term Assessment of the Safety and Efficacy of PA21 (Sucroferric Oxyhydroxide) in Japanese Hemodialysis Patients With Hyperphosphatemia: An Open-Label, Multicenter, Phase III Study. *Journal of Renal Nutrition*, **2017**, 27, 346-354	3	8
103	Magnesium as a new player in CKD: too little is as bad as too much?. *Kidney International*, **2017**, 92, 1034-1036	9.9	8
102	Design and baseline characteristics of the LANDMARK study. *Clinical and Experimental Nephrology*, **2017**, 21, 531-537	2.5	8
101	Molecular Abnormalities Underlying Bone Fragility in Chronic Kidney Disease. *BioMed Research International*, **2017**, 2017, 3485785	3	8
100	Treatment with pravastatin attenuates oxidative stress and protects osteoblast cell viability from indoxyl sulfate. *Therapeutic Apheresis and Dialysis*, **2011**, 15, 151-5	1.9	8
99	Parathyroidectomy markedly reduces oxidative stress in a patient with primary hyperparathyroidism. *Therapeutic Apheresis and Dialysis*, **2011**, 15 Suppl 1, 38-41	1.9	8
98	Restoration of reversed whole PTH/intact PTH ratio and reduction in parathyroid gland vascularity during cinacalcet therapy for severe hyperparathyroidism in a uraemic patient. *Nephrology Dialysis Transplantation*, **2010**, 25, 638-41	4.3	8
97	Parathyroid resistance to FGF23 in kidney transplant recipients: back to the past or ahead to the future?. *Kidney International*, **2010**, 78, 953-5	9.9	8
96	Pathogenesis and medical treatment of secondary hyperparathyroidism. *Journal of Surgical Oncology*, **1997**, 13, 73-7		8
95	Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2021**, 325, 1946-1954	27.4	8
94	The cardiothoracic ratio and all-cause and cardiovascular disease mortality in patients undergoing maintenance hemodialysis: results of the MBD-5D study. *Clinical and Experimental Nephrology*, **2017**, 21, 797-806	2.5	7
93	Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients. *Clinical and Experimental Nephrology*, **2019**, 23, 739-748	2.5	7
92	Cinacalcet and Clinical Outcomes in Dialysis. *Seminars in Dialysis*, **2015**, 28, 594-603	2.5	7

91	Pharmacotherapy and interventional treatments for secondary hyperparathyroidism: current therapy and future challenges. *Expert Opinion on Biological Therapy*, **2010**, 10, 1729-42	5.4	7
90	Serum total indoxyl sulfate and clinical outcomes in hemodialysis patients: results from the Japan Dialysis Outcomes and Practice Patterns Study. *CKJ: Clinical Kidney Journal*, **2021**, 14, 1236-1243	4.5	7
89	Optimizing the cost-effectiveness of treatment for chronic kidney disease-mineral and bone disorder. *Kidney International Supplements*, **2013**, 3, 457-461	6.3	6
88	Association between long-term efficacy of cinacalcet and parathyroid gland volume in haemodialysis patients with secondary hyperparathyroidism. *CKJ: Clinical Kidney Journal*, **2008**, 1, iii49-iii53	4.5	6
87	Direct injection of calcitriol or its analog improves abnormal gene expression in the hyperplastic parathyroid gland in uremia. *American Journal of Nephrology*, **2008**, 28, 59-66	4.6	6
86	The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation. *Nephrology Dialysis Transplantation*, **2021**, 36, 160-169	4.3	6
85	A rare case of Cushingβ syndrome due to bilateral adrenocortical adenomas. *Tokai Journal of Experimental and Clinical Medicine*, **2014**, 39, 158-65	0.4	6
84	Oral Ferric Citrate Hydrate Associated With Less Oxidative Stress Than Intravenous Saccharated Ferric Oxide. *Kidney International Reports*, **2018**, 3, 364-373	4.1	5
83	TGF-Beta Signaling in Bone with Chronic Kidney Disease. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	5
82	In and out of the bone: can the osteocyte escape skeletal jail and yet regulate mineralization?. *Kidney International*, **2014**, 85, 11-2	9.9	5
81	Towards cost-effective strategies for treatment of chronic kidney disease-mineral and bone disorder in Japan. *Therapeutic Apheresis and Dialysis*, **2009**, 13 Suppl 1, S28-35	1.9	5
80	Advanced oxidation protein products contribute to chronic kidney disease-induced muscle atrophy by inducing oxidative stress via CD36/NADPH oxidase pathway. *Journal of Cachexia, Sarcopenia and Muscle*, **2021**,	10.3	5
79	Indoxyl Sulfate Contributes to Adipose Tissue Inflammation through the Activation of NADPH Oxidase. *Toxins*, **2020**, 12,	4.9	5
78	The Pituitary Is a Candidate Organ That Modulates Circulating Klotho Levels. *Journal of the Endocrine Society*, **2019**, 3, 52-61	0.4	5
77	Type I Angiotensin II Receptor Blockade Reduces Uremia-Induced Deterioration of Bone Material Properties. *Journal of Bone and Mineral Research*, **2021**, 36, 67-79	6.3	5
76	Adrenal Venous Sampling Is Useful for a Definitive Diagnosis in Cushingβ Syndrome with Bilateral Adrenal Tumors. *Tokai Journal of Experimental and Clinical Medicine*, **2015**, 40, 149-56	0.4	5
75	Chronic Kidney Disease-Mineral and Bone Disorder in Asia. *Kidney Diseases (Basel, Switzerland)*, **2017**, 3, 1-7	3.3	4
74	Pattern of Laboratory Parameters and Management of Secondary Hyperparathyroidism in Countries of Europe, Asia, the Middle East, and North America. *Advances in Therapy*, **2020**, 37, 2748-2762	4.1	4

73	Endocrine fibroblast growth factors as potential biomarkers for chronic kidney disease. *Expert Review of Molecular Diagnostics*, **2020**, 20, 715-724	3.8	4
72	Metacarpal bone mineral density by radiographic absorptiometry predicts fracture risk in patients undergoing maintenance hemodialysis. *Kidney International*, **2020**, 98, 970-978	9.9	4
71	Efficacy and Safety of Sucroferric Oxyhydroxide and Calcium Carbonate in Hemodialysis Patients. *Kidney International Reports*, **2018**, 3, 185-192	4.1	4
70	Novel electrochemiluminescence immunoassay exclusively for full-length parathyroid hormone during treatment with cinacalcet for secondary hyperparathyroidism. *Therapeutic Apheresis and Dialysis*, **2011**, 15 Suppl 1, 56-61	1.9	4
69	Management of mineral and bone disorder in chronic kidney disease: quo vadis?. *Therapeutic Apheresis and Dialysis*, **2009**, 13 Suppl 1, S2-6	1.9	4
68	New clinical guidelines for selective direct injection therapy of the parathyroid glands in chronic dialysis patients. *CKJ: Clinical Kidney Journal*, **2008**, 1, iii26-iii28	4.5	4
67	The whole-PTH/intact-PTH ratio is a useful predictor of severity of secondary hyperparathyroidism. *CKJ: Clinical Kidney Journal*, **2008**, 1, iii59-iii62	4.5	4
66	Shunt nephritis: efficacy of an antibiotic trial for clinical diagnosis. *Internal Medicine*, **1993**, 32, 291-4	1.1	4
65	Changes in Fibroblast Growth Factor 23 and Soluble Klotho Levels After Hemodialysis Initiation. *Kidney Medicine*, **2020**, 2, 59-67	2.8	4
64	Advanced Oxidation Protein Products Contribute to Renal Tubulopathy Perturbation of Renal Fatty Acids.. *Kidney360*, **2020**, 1, 781-796	1.8	4
63	Old and New Drugs for the Management of Bone Disorders in CKD. *Calcified Tissue International*, **2021**, 108, 486-495	3.9	4
62	Effect of Tenapanor on Phosphate Binder Pill Burden in Hemodialysis Patients. *Kidney International Reports*, **2021**, 6, 2371-2380	4.1	4
61	A Liquid-Based Cytology System, without the Use of Cytocentrifugation, for Detection of Podocytes in Urine Samples of Patients with Diabetic Nephropathy. *Journal of Diabetes Research*, **2019**, 2019, 9475637	3.9	3
60	22-Oxacalcitriol attenuates bone loss in nonobese type 2 diabetes. *Bone*, **2015**, 74, 153-9	4.7	3
59	Global Dialysis Perspective: Japan.. *Kidney360*, **2020**, 1, 416-419	1.8	3
58	Skeletal and mineral metabolic effects of risedronate in a rat model of high-turnover renal osteodystrophy. *Journal of Bone and Mineral Metabolism*, **2020**, 38, 501-510	2.9	3
57	Frequent monitoring of mineral metabolism in hemodialysis patients with secondary hyperparathyroidism: associations with achievement of treatment goals and with adjustments in therapy. *Nephrology Dialysis Transplantation*, **2017**, 32, 534-541	4.3	3
56	Behavior Modification Maintenance with Long-Term Blood Glucose and Weight Management in Prader-Willi Syndrome Complicated with Diabetes: Team Management Approach Combined with Pharmacological Treatment. *Case Reports in Medicine*, **2019**, 2019, 6129019	0.7	3

55	Interactive Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers or Their Combination on Survival of Hemodialysis Patients. *American Journal of Nephrology* , **2017**, 46, 439-447	4.6	3
54	Introduction: expanding concepts of chronic kidney disease-mineral and bone disorder (CKD-MBD). *Kidney International Supplements*, **2013**, 3, 419	6.3	3
53	Reversed whole PTH/intact PTH ratio as an indicator of marked parathyroid enlargement: five case studies and a literature review. *CKJ: Clinical Kidney Journal*, **2008**, 1, iii54-iii58	4.5	3
52	Can calcimimetics inhibit nodular hyperplasia of parathyroid glands?. *Nephrology Dialysis Transplantation*, **2008**, 23, 407-8; author reply 408-9	4.3	3
51	Nivolumab-induced fulminant type□1 diabetes with precipitous fall in C-peptide level. *Journal of Diabetes Investigation*, **2020**, 11, 748-749	3.9	3
50	Influence of dialysate Ca concentrations on the therapeutic effects of etelcalcetide with concomitant drugs in patients with secondary hyperparathyroidism. *Nephrology*, **2020**, 25, 634-643	2.2	3
49	An acute phase protein □acid glycoprotein mitigates AKI and its progression to CKD through its anti-inflammatory action. *Scientific Reports*, **2021**, 11, 7953	4.9	3
48	Secondary hyperparathyroidism, weight loss, and longer term mortality in haemodialysis patients: results from the DOPPS. *Journal of Cachexia, Sarcopenia and Muscle*, **2021**, 12, 855-865	10.3	3
47	Assessment of the accuracy of an intermittent-scanning continuous glucose monitoring device in patients with type 2 diabetes mellitus undergoing hemodialysis (AIDT2H) study. *Therapeutic Apheresis and Dialysis*, **2021**, 25, 586-594	1.9	3
46	Parathyroid hormone-producing cells exist in adipose tissues surrounding the parathyroid glands in hemodialysis patients with secondary hyperparathyroidism. *Scientific Reports*, **2020**, 10, 3290	4.9	2
45	Magnesium as a Janus-faced inhibitor of calcification. *Kidney International*, **2020**, 97, 448-450	9.9	2
44	Relationship between serum calcium or phosphate levels and mortality stratified by parathyroid hormone level: an analysis from the MBD-5D study. *Clinical and Experimental Nephrology*, **2020**, 24, 630-637	2.5	2
43	Overt intracardiac shunt flow after arteriovenous graft placement. *Clinical and Experimental Nephrology*, **2013**, 17, 592-3	2.5	2
42	Development of a technique for introduction of an expressed complementary deoxyribonucleic acid into parathyroid cells by direct injection. *Endocrinology*, **2010**, 151, 4031-8	4.8	2
41	Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan-A Phase 2 Randomized Trial.. *Kidney International Reports*, **2022**, 7, 177-188	4.1	2
40	Jury still out on whether FGF23 is a direct contributor, a useful biomarker, or neither. *Kidney International*, **2021**, 100, 989-993	9.9	2
39	Fibroblast Growth Factor 23 and Mortality Among Prevalent Hemodialysis Patients in the Japan Dialysis Outcomes and Practice Patterns Study. *Kidney International Reports*, **2020**, 5, 1956-1964	4.1	2
38	Therapeutic Effects of Add-On Tenapanor for Hemodialysis Patients with Refractory Hyperphosphatemia. *American Journal of Nephrology*, **2021**, 52, 496-506	4.6	2

37	Population-level associations of achievement of targets for bone-mineral markers with survival in haemodialysis patients with mildly elevated intact-PTH levels: a case-cohort study. *Scientific Reports*, **2019**, 9, 11301	4.9	1
36	Response to Comments on "Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study". *Clinical Drug Investigation*, **2019**, 39, 109-111	3.2	1
35	Semiquantitative analysis of virtual histology derived from intravascular ultrasound images at vascular access stenosis. *Journal of Vascular Access*, **2019**, 20, 55-59	1.8	1
34	Effectiveness of cinacalcet treatment for secondary hyperparathyroidism on hospitalization: Results from the MBD-5D study. *PLoS ONE*, **2019**, 14, e0216399	3.7	1
33	Development of evocalcet for unmet needs among calcimimetic agents. *Expert Review of Endocrinology and Metabolism*, **2020**, 15, 299-310	4.1	1
32	International and Racial Differences in Mineral and Bone Disorder Markers and Treatments Over the First 5 Years of Hemodialysis in the Dialysis Outcomes and Practice Patterns Study. *Kidney Medicine*, **2019**, 1, 86-96	2.8	1
31	Feasibility of photodynamic therapy for secondary hyperparathyroidism in chronic renal failure rats. *Clinical and Experimental Nephrology*, **2017**, 21, 563-572	2.5	1
30	Dialysis: Effect of cinacalcet on survival--the saga continues. *Nature Reviews Nephrology*, **2013**, 9, 435-6	14.9	1
29	A Retrospectively Diagnosed Case of IgG4-Related Tubulointerstitial Nephritis Showing Good Renal Outcome and Pathological Progress. *Case Reports in Nephrology*, **2013**, 2013, 953214	0.8	1
28	Amino-terminal form of parathyroid hormone in CKD. *Kidney International*, **2010**, 78, 110-1; author reply 111	9.9	1
27	Acid Glycoprotein Attenuates Adriamycin-Induced Nephropathy CD163 Expressing Macrophage Induction.. *Kidney360*, **2020**, 1, 343-353	1.8	1
26	Changes in 3-month mineral and bone disorder patterns were associated with all-cause mortality in prevalent hemodialysis patients with secondary hyperparathyroidism. *BMC Nephrology*, **2020**, 21, 432	2.7	1
25	Medical Director Practice of Advising Increased Dietary Protein Intake in Hemodialysis Patients With Hyperphosphatemia: Associations With Mortality in the Dialysis Outcomes and Practice Patterns Study. *Journal of Renal Nutrition*, **2021**,	3	1
24	MP368A NOVEL INTRAVENOUS CALCIMIMETIC, ONO-5163 (ETELCALCETIDE): A MULTICENTER, SINGLE AND MULTIPLE DOSE STUDY IN JAPANESE HEMODIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM. *Nephrology Dialysis Transplantation*, **2016**, 31, i462-i462	4.3	1
23	Efficacy of Evocalcet in Previously Cinacalcet-Treated Secondary Hyperparathyroidism Patients. *Kidney International Reports*, **2021**, 6, 2830-2839	4.1	1
22	Interrelationships between sclerostin, secondary hyperparathyroidism, and bone metabolism in patients on hemodialysis. *Journal of Clinical Endocrinology and Metabolism*, **2021**,	5.6	1
21	Cardiovascular disease history and blocker prescription patterns among Japanese and American patients with CKD: a cross-sectional study of the CRIC and CKD-JAC studies. *Hypertension Research*, **2021**, 44, 700-710	4.7	1
20	A Case of Encapsulating Peritoneal Sclerosis Complicated by Malignant Peritoneal Mesothelioma. *Tokai Journal of Experimental and Clinical Medicine*, **2016**, 41, 135-8	0.4	1

19	Vitamin D supplementation in renal disease: is calcitriol all that is needed?. *Scandinavian Journal of Clinical and Laboratory Investigation, Supplement*, **2012**, 243, 120-3		1
18	Efficacy and Safety of Evocalcet Evaluated by Dialysate Calcium Concentration in Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis. *International Journal of Nephrology and Renovascular Disease*, **2020**, 13, 97-106	2.5	0
17	Molecular basis for the management of secondary hyperparathyroidism in chronic renal failure. *Artificial Organs*, **1995**, 19, 1210-4	2.6	0
16	Association of fibroblast growth factor 23 and α-klotho in hemodialysis patients during administration of ferric citrate hydrate: post hoc analysis of ASTRIO study. *BMC Nephrology*, **2021**, 22, 374	2.7	0
15	Post-kidney transplant soluble Klotho levels are determined by pretransplant soluble Klotho levels in both living donors and recipients. *Clinical and Experimental Nephrology*, **2021**, 25, 1367-1374	2.5	0
14	FGF23 and Klotho in Chronic Kidney Disease **2020**, 57-64		0
13	Ferric citrate hydrate is associated with a reduced cost of drugs and a smaller change in red blood cell distribution width.. *Scientific Reports*, **2022**, 12, 2406	4.9	0
12	First-in-Human Phase I Study of the Novel Injectable Calcimimetic Agent Upacicalcet in Healthy Adult Japanese Participants.. *Drugs in R and D*, **2022**, 1	3.4	0
11	Glucocorticoid Receptor Antagonist Administration Prevents Adrenal Gland Atrophy in an ACTH-Independent Cushing's Syndrome Rat Model. *International Journal of Endocrinology*, **2019**, 2019, 8708401	2.7	
10	The Authors Reply. *Kidney International*, **2015**, 88, 638-9	9.9	
9	Hypokalemia Events With Sodium Zirconium Cyclosilicate and Placebo in Hemodialysis Patients.. *Kidney International Reports*, **2022**, 7, 908-912	4.1	
8	Potassium responses to sodium zirconium cyclosilicate in hyperkalemic hemodialysis patients: post-hoc analysis of DIALIZE.. *BMC Nephrology*, **2022**, 23, 59	2.7	
7	Uremic Toxicity and Bone in CKD **2020**, 95-114		
6	PTH Regulation by the Klotho/FGF23 Axis in CKD **2020**, 21-34		
5	5. Mineral Metabolism in Chronic Kidney Disease. *The Journal of the Japanese Society of Internal Medicine*, **2016**, 105, 1784-1788	0	
4	Results of a survey on practice patterns at the end of a study involving CKD-MBD management at dialysis facilities. *Nihon Toseki Igakkai Zasshi*, **2013**, 46, 193-200	0.3	
3	Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: results of a post-marketing surveillance in Japan. *Clinical and Experimental Nephrology*, **2021**, 25, 66-79	2.5	
2	Evocalcet with vitamin D receptor activator treatment for secondary hyperparathyroidism.. *PLoS ONE*, **2022**, 17, e0262829	3.7	

1 Course of Hyperkalemia in Patients on Hemodialysis.. *International Journal of Nephrology*, **2022**, 2022, 6304571 1.7